12 Results for "

BsAb

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "BsAb" in MCE Product Catalog:

Cat. No.: HY-P99601
CAS No.: 2249888-53-5
Synonyms: BFCR 4350A; RG 6160; RO 7187797

Target:  

CD3

Research Areas:  

Neurological Disease Cancer

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .
loading...
    loading...
Cat. No.: HY-P99419
CAS No.: 2253937-12-9
Synonyms: GEN1046

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .
loading...
    loading...
Cat. No.: HY-P991440

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

AMG-966 is a human bispecific antibody (bsAb) targeting TNFSF15/TL1A & TNFα. AMG 966 restores the ability of the aglycosylated Fc domain to bind FcγRIa and FcγRIIa, leading to the formation of anti-drug antibodies (ADA). AMG 966 can be used in research on Crohn's disease and ulcerative colitis. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P99562
CAS No.: 2148354-90-7
Synonyms: XmAb-18087

Target:  

CD3

Research Areas:  

Cancer

Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
loading...
    loading...
Cat. No.: HY-P99757
CAS No.: 2278244-14-5
Synonyms: Hu3F8-BsAb

Target:  

CD3

Research Areas:  

Cancer

Nivatrotamab (Hu3F8-BsAb) is a bispecific antibody targeting GD2 and CD3, with KD values of 5.8 nM and 194 nM, respectively. Nivatrotamab redirects T cells to tumor sites and activates immune synapses, thereby mediating antibody-dependent T cell-mediated cytotoxicity. Nivatrotamab induces specific tumor cytotoxicity, stimulates the release of Th1 cytokines and promotes immune cell infiltration into tumors. In addition, its Fc segment deglycosylation design effectively prevents complement activation and cytokine storm. Nivatrotamab can be widely used in research related to various solid tumors, including melanoma, neuroblastoma, osteosarcoma, small cell lung cancer, breast cancer, Ewing's sarcoma, colon cancer, ovarian cancer and rhabdomyosarcoma .
loading...
    loading...
Cat. No.: HY-P99776
CAS No.: 2138442-31-4
Synonyms: XmAb-13676
Target:  

CD20 CD3

Research Areas:  

Cancer

Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
loading...
    loading...
Cat. No.: HY-P990742
CAS No.: 2762499-30-7
Synonyms: TJ-CD4B; ABL111; TJ033721

Target:  

TNF Receptor Claudin

Research Areas:  

Inflammation/Immunology Cancer

Givastomig (ABL111, TJ033721) is a bispecific antibody (BsAb) inhibitor. Givastomig can specifically binds to Claudin18.2 (CLDN 18.2) on the surface of cancer cells and 4-1BB (CD137, TNFRSF9) on the surface of activated T cells and natural killer (NK) cells. Givastomig is engineered to contain a single Fc-domain mutation (asparagine to alanine) to eliminate Fc-effector function. Givastomig-bound cell lines expressing a range of CLDN18.2 levels with high affinity and induced 4-1BB activation only in the context of CLDN18.2 binding. Givastomig can be used for the study of colon carcinoma .
loading...
    loading...
Cat. No.: HY-P990913
CAS No.: 2765077-69-6
Synonyms: BsAb7075; REGN-7075; Marlotamig

Target:  

EGFR

Research Areas:  

Inflammation/Immunology

HY-P990913 is an EGFR/CD28-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
Cat. No.: HY-P991324

Research Areas:  

Inflammation/Immunology

MEDI-7352 is a human bispecific antibody (bsAb) targeting NGF/bNGF & TNF. MEDI-7352 can be used in osteoarthritis (OA) pain research .
loading...
    loading...
Cat. No.: HY-P991463

Target:  

CD3

Research Areas:  

Cancer

MS133 is a human bispecific antibody (bsAb) targeting CD133/PROM1 & CD3E. MS133 can be used in colon cancer research .
loading...
    loading...
Cat. No.: HY-P991461
Synonyms: XmAb968

Target:  

CD38

Research Areas:  

Cancer

AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 & CD3E. AMG-424 kills CD38-expressing cancer cells, triggers T-cell proliferation and attenuates cytokine release. AMG 424 has antitumor activity in a bone marrow-invasive mouse cancer model and induces peripheral B-cell depletion in cynomolgus monkeys. AMG-424 can be used in multiple myeloma research. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
loading...
    loading...
Cat. No.: HY-P991462

Target:  

CD38

Research Areas:  

Cancer

GBR-1342 is a human bispecific antibody (bsAb) targeting CD38 & CD3. GBR-1342 inhibits the activity of Daudi, RAJI, RPMI8226, IM-9, and NCI-H929 cancer cell lines. GBR-1342 can be used in myeloma research .
loading...
    loading...
  • 1